In fact, GO was granted approval by the FDA in 2000 for the treatment of relapsed CD33-positive AML patients that were not considered candidates for cytotoxic chemotherapy and were over the age of 60 based on three open label trails showing a 30% complete response rate and favorable safety profile [35,76]. This evidence concerns the gene CD33 and acute myeloid leukemia.